Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial - PubMed (original) (raw)
Clinical Trial
. 1991 Apr 1;114(7):525-31.
doi: 10.7326/0003-4819-114-7-525.
Affiliations
- PMID: 1848053
- DOI: 10.7326/0003-4819-114-7-525
Clinical Trial
Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial
S A Plotkin et al. Ann Intern Med. 1991.
Abstract
Objective: To test the efficacy of vaccination with the Towne live attenuated cytomegalovirus vaccine.
Design: A double-blind, randomized, placebo-controlled trial in candidates for renal transplantation. The cytomegalovirus serologic status of both recipients and donors were determined, and the recipients were followed for periods of 6 months to 7 years after transplant.
Setting: A university transplant center.
Patients: The analyses were made on 237 patients who were given either vaccine or placebo, received renal transplants, and were followed for at least 6 months.
Intervention: Subcutaneous inoculation with Towne live attenuated virus or with placebo.
Main outcome measures: The presence of cytomegalovirus infection was defined by virus isolation and antibody tests. If infection occurred, a prearranged scoring system for cytomegalovirus disease was used to objectify disease severity.
Results: The vaccine was well tolerated, and there were no discernible long-term adverse effects. Recipients who were originally seropositive did not clearly benefit from vaccination. Protective efficacy was analyzed in the group at highest risk for cytomegalovirus disease; recipients who were seronegative at the time of vaccination and who received a kidney from a seropositive donor. Compared with placebo recipients, vaccinated patients in this group had significantly less severe cytomegalovirus disease, with a significant reduction in disease scores (P = 0.03) and 85% decrease in the most severe disease (95% CI, 35% to 96%), although infection rates were similar. Graft survival at 36 months was improved in vaccinated recipients of cadaver kidneys (8 of 16) compared with unvaccinated recipients (4 of 16) (P = 0.04).
Conclusions: Previous vaccination of seronegative renal transplant recipients with live cytomegalovirus results in reduction of disease severity mimicking the action of naturally derived immunity.
Comment in
- Acyclovir to prevent cytomegalovirus infection after renal transplantation.
Wong T, Toupance O, Chanard J. Wong T, et al. Ann Intern Med. 1991 Jul 1;115(1):68. doi: 10.7326/0003-4819-115-1-68_1. Ann Intern Med. 1991. PMID: 1646586 No abstract available. - Options for prevention of cytomegalovirus disease.
Balfour HH Jr. Balfour HH Jr. Ann Intern Med. 1991 Apr 1;114(7):598-9. doi: 10.7326/0003-4819-114-7-598. Ann Intern Med. 1991. PMID: 1848055 No abstract available.
Similar articles
- Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial.
Brayman KL, Dafoe DC, Smythe WR, Barker CF, Perloff LJ, Naji A, Fox IJ, Grossman RA, Jorkasky DK, Starr SE, et al. Brayman KL, et al. Arch Surg. 1988 Dec;123(12):1502-8. doi: 10.1001/archsurg.1988.01400360072012. Arch Surg. 1988. PMID: 2847687 Clinical Trial. - Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.
Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell DA Jr, Shope TC, Spector SA, Dankner WM. Plotkin SA, et al. Transplantation. 1994 Dec 15;58(11):1176-8. Transplantation. 1994. PMID: 7992358 Clinical Trial. - Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.
Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, Dafoe DC, Friedman AD, Grossman RA, Barker CF. Plotkin SA, et al. Lancet. 1984 Mar 10;1(8376):528-30. doi: 10.1016/s0140-6736(84)90930-9. Lancet. 1984. PMID: 6142252 Clinical Trial. - Vaccines for the prevention of human cytomegalovirus infection.
Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K. Plotkin SA, et al. Rev Infect Dis. 1990 Sep-Oct;12 Suppl 7:S827-38. doi: 10.1093/clinids/12.supplement_7.s827. Rev Infect Dis. 1990. PMID: 2173112 Review. - The status of cytomegalovirus vaccine.
Starr SE, Friedman HM, Plotkin SA. Starr SE, et al. Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S964-5. doi: 10.1093/clind/13.supplement_11.s964. Rev Infect Dis. 1991. PMID: 1664136 Review.
Cited by
- Therapeutic vaccines for herpesviruses.
Cohen JI. Cohen JI. J Clin Invest. 2024 May 1;134(9):e179483. doi: 10.1172/JCI179483. J Clin Invest. 2024. PMID: 38690731 Free PMC article. Review. - Human cytomegalovirus in cancer: the mechanism of HCMV-induced carcinogenesis and its therapeutic potential.
Yu C, He S, Zhu W, Ru P, Ge X, Govindasamy K. Yu C, et al. Front Cell Infect Microbiol. 2023 Jun 23;13:1202138. doi: 10.3389/fcimb.2023.1202138. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37424781 Free PMC article. Review. - Cytomegalovirus Infections in Children with Primary and Secondary Immune Deficiencies.
Bateman CM, Kesson A, Powys M, Wong M, Blyth E. Bateman CM, et al. Viruses. 2021 Oct 5;13(10):2001. doi: 10.3390/v13102001. Viruses. 2021. PMID: 34696432 Free PMC article. Review. - Insight for Immunotherapy of HCMV Infection.
Long X, Qiu Y, Zhang Z, Wu M. Long X, et al. Int J Biol Sci. 2021 Jul 13;17(11):2899-2911. doi: 10.7150/ijbs.58127. eCollection 2021. Int J Biol Sci. 2021. PMID: 34345215 Free PMC article. Review. - Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice.
Scarpini S, Morigi F, Betti L, Dondi A, Biagi C, Lanari M. Scarpini S, et al. Vaccines (Basel). 2021 May 25;9(6):551. doi: 10.3390/vaccines9060551. Vaccines (Basel). 2021. PMID: 34070277 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical